HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, announced that its management team will participate in several investor and industry conferences throughout March 2026. CEO Robert Eno and CFO Timothy Cruickshank will attend the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 16-17, which will include a webcast presentation on March 16 and meetings with institutional and retail investors.
The executives will also participate in the 38th Annual ROTH Conference in Dana Point, California, on March 23-24, where Eno will join a panel discussion on technologies advancing healthy aging. Additionally, Eno, Founder and President Dr. Branislav Vajdic, and Chief Commercial Officer Bryan Humbarger will attend ACC.26, the American College of Cardiology's annual scientific conference on March 28-30. At this cardiology event, the company plans to showcase its FDA-cleared HeartBeam System and demonstrate a working prototype of its 12-lead ECG extended wear patch to physicians and potential industry partners.
HeartBeam is developing what it describes as the first-ever cable-free device capable of collecting electrocardiogram (ECG) signals in three dimensions from three non-coplanar directions and synthesizing those signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever a patient is located to deliver actionable heart intelligence. The company's approach aims to enable physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of traditional medical facilities.
The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and its 12-lead ECG synthesis software received FDA clearance in December 2025. HeartBeam holds over 20 issued patents related to its technology enablement. The company's news and updates are available in its newsroom at https://ibn.fm/BEAT.
These conference appearances come at a significant time for the medical technology sector, particularly in cardiac care where remote monitoring solutions are gaining increased attention. The demonstration of HeartBeam's extended wear patch prototype at ACC.26 represents a key opportunity to engage directly with cardiologists who would ultimately use such technology in clinical practice. The investor conferences provide platforms to communicate the company's progress and vision to the financial community as it seeks to commercialize its FDA-cleared technologies.
The implications of HeartBeam's technology extend beyond the company itself to the broader healthcare landscape. If successfully implemented, portable 3D ECG devices could potentially reduce healthcare costs by enabling earlier detection of cardiac issues outside clinical settings and decreasing unnecessary emergency room visits. The technology aligns with growing trends toward telehealth and remote patient monitoring, which have accelerated in recent years. However, as noted in the company's forward-looking statements available at http://IBN.fm/Disclaimer, actual results may differ from expectations due to various risks and uncertainties.
